

# EHDN2021 Remote Meeting, Sep. 9 – 11

#### **Meeting Host: Patrick Weydt**

THURSDAY, SEPTEMBER 9th, 2021

- 14:00 14:30 WELCOME AND INTRODUCTION + EHDN Business (Constitution + Voting Results) Anne Rosser, Astri Arnesen, Patrick Weydt
- 14:30 15:00 KEYNOTE SESSION I: From fruitfly biorhythm genetics to Huntington's Charalambos P. Kyriacou
- 15:00 16:00 PLENARY SESSION I: Genetic modifiers of HD: DNA damage and somatic expansion of repeats Chaired by Lesley Jones and Davina Hensman

 Gene editing for expanded CAG/CTG repeat disorders: making a long story short (20 min) Vincent Dion
 Using histone deacetylase 3 inhibition to rein in HD expansion mutations (20 min) Bob Lahue
 Dissecting Genetic Modifiers of HD: Towards Understanding Mechanism (20 min) Vanessa Wheeler

- 16:00 16:30 BREAK
- 16.30 16.35 Announcement: HDYO donation Matthew Ellison
- 16:35 17:35 PLENARY SESSION II: Cognition

Chaired by Jaime Kulisevsky and Saul Martinez-Horta **1. Session presentation** (5 min) Saul Martinez-Horta **2. Visual system integrity in Huntington's disease** (20 min) Michael Orth **3. Hippocampal-dependent memory in Huntington's disease** (20 min) Julie Stout **4. Q&A** (10 min) **5. Closing remarks** (5 min) Jaime Kulisevsky

## 17:35 - 18:35 SHORT COMMUNICATIONS I

Chaired by: Esther Cubo and Lauren Byrne

**1. Research Participation: The View of Persons at Risk and Persons with Premanifest HD** Filipa Júlio

2. Huntington's Disease Burden of Illness (HDBOI): Study Methodology, Sample Representativeness and Fieldwork Risk Mitigation Strategy During the COVID-19 Pandemic Idaira Rodríguez

**3. Safety and Tolerability of Lumbar Punctures (LP) Procedure in Patients with HD** Yara Hassan

**4. Skill-Based Dysphagia Training as an Intervention for Individuals with HD** Emma Burnip

5. Introducing JOIN-HD: The Juvenile Onset Initiative for Huntington's Disease Rebecca Mason



- 18:35 18:50 ROUND-UP and Goodbye for the day Host Patrick Weydt and guest(s) of the day
- 18:50-19:00 BREAK
- 19:00 20:00 POSTER SESSION: meet the poster presenter

#### FRIDAY, SEPTEMBER 10th, 2021

- 13:00-14:00 POSTER SESSION: meet the poster presenter
- 14:00 14:05 Announcement: MDS/EHDN teaching course Michael Orth
- 14:05 15:35 PLENARY SESSION III: Clinical Trial Session Chaired by: Ralf Reilmann and Dina de Sousa

**1.** Roche – An update from the tominersen clinical development programme (15 min) Scott Schobel **2.SIGNAL/Vaccinex – results and lessons learnt** (15 min) **Maurice Zauderer** 3. SELECT-HD, an adaptive first-in-human clinical trial to evaluate WVE-003, an investigational allele-selective mHTT-lowering oligonucleotide, in early manifest Huntington's disease (15 min) Vissia Viglietta 4. UniQure – An update on HD-GeneTRX-1 and HD-GeneTRX-2 - Phase 1 / 2 Clinical Trials of AMT-**130 Gene Therapy for early stage HD** (15 min) **David Cooper** 5. Development of TTX-3360 to prevent onset and/or progression in HD and other Repeat **Expansion Disorders by Halting Somatic Expansion** (15 min) Irina Antonijevic 6. PROOF-HD – update on the status of the phase III clinical trial of pridopidine aiming to improve global function in early stage HD (15 min) Michael Hayden

- 15:35 15:45 BREAK
- 15:45 16:30 PANEL DISCUSSION: What are the lessons learned in the drug development process? Chaired by: Ralf Reilmann and Dina de Sousa With the Speakers from Plenary Session III
- 16:30 16:45 BREAK
- 16:45 17:45 PARALLEL SESSIONS

**Neuro-Development** Chaired by: Sandrine Humbert and Silvia Gines

 Huntington's disease alters cortical development in mouse and human (20 min) Monia Barnat
 Pediatric onset Huntington disease: neuro developmental delay or early Multidisciplinary care Chaired by: Marleen van Walsem and Ruth Veenhuizen

 Introduction (5 min): Multidisciplinary care and treatment: focus on care in advanced stages: challenges and approaches for managing
 Challenges and practise-based approaches in professional advanced care (15 min) Marleen van Walsem



neurodegeneration? (20 min)
Ferdinando Squitieri **3. Specific developmental alterations of striatal**subpopulations in Huntington's disease (20 min)
Josep Canals

3. Patients with Huntington's disease living in a nursing home: characteristics, functioning, and gender differences (15 min)
Ruth Veenhuizen
4. Passivities of daily living (15 min)
Manon van Kampen
5. Discussion (10 min)

#### 17:45 - 18:45 SHORT COMMUNICATIONS II

Chaired by: Ahmad Aziz and Maria Björkqvist

Fronto-Striatal Circuits for Cognitive Flexibility in far from Onset Huntington's Disease:
 Evidence from the Young Adult Study
 Christelle Langley
 Mutation-Related Apparent Myelin, not Axon Density, Drives White Matter Pathology in
 Premanifest Huntington's Disease: Evidence from in Vivo Ultra-Strong Gradient MRI
 Chiara Casella
 A Different Depression: Antidepressant Efficacy and Cognitive Mechanisms of Mood Disorder in Huntington's Disease
 Duncan McLauchlan
 Clinical Translation of Stem Cell Therapies for Huntington's Disease (HD)
 Anne Rosser
 Triheptanoin is Associated with Clinical Stability and Decreased Caudate Atrophy in HD
 Fanny Mochel
 Comparison of Cognitive Mechanism Caudate Atrophy in HD
 Fanny Mochel
 Comparison of Cognitive Action Cognition
 Content of Comparison of Comparison of Cognition
 Cognition

- 18:45 19:00
   ROUND-UP and Goodbye for the day

   Host Patrick Weydt and guest(s) of the day
- 19:00 20:00 POSTER SESSION: meet the poster presenter

### SATURDAY, SEPTEMBER 11th, 2021

## 13:00 - 14:00 POSTER SESSION: meet the poster presenter

14:00 - 15:00 SHORT COMMUNICATIONS III Chaired by: Kathrin Reetz and Nayana Lahiri

> FAN1 Controls CAG Repeat Expansion in Huntington's Disease by Dual Functions, MLH1 Retention and Nuclease Activity Joseph Hamilton
>  Striatal Procedural Memory-Induced Transcriptome and Epigenome are Severely Impaired in Huntington's Disease Mice Rafael Alcalá-Vida
>  A New In Vivo and In Vitro Single-Cell Atlas of Developing Medium Spiny Neurons to Guide Future Improvements for Huntington Disease Cell-Replacement Therapies and Disease Modelling Vittoria Bocchi
>  Huntingtin-Mediated Axonal Transport Requires Arginine Methylation by PRMT6 Alice Migazzi
>  The 'Hold me Tight' Relationship Program for Couples Facing Huntington's Disease



### 15:00 - 16:00 PARALLEL SESSIONS

#### Digital Technologies to Advance Assessment and Care in HD

Chaired by Alzbeta Mühlbäck and Monica Busse

Sleep, circadian rhythm and metabolism in HD Chaired by: Patrick Weydt and Asa Petersen

 Introduction to the session: Landscape View of the Field (15 min) Monica Busse
 IDEA-FAST (15 min) Ralf Reilmann
 eHealth Platform for HD overview (10 min) Pearl van Lonkhuizen
 DOMINO-HD overview (10 min) Philippa Jones
 Panel Discussion: Ethical & practical challenges (10min) All speakers and chairs  Introduction to the topic by the chairs
 Sleep and metabolism in Huntington disease (15 min)
 Roger Barker
 Clock genes and circadian rhythm (15 min)
 Charalambos P. Kyriacou
 Targeting cholesterol metabolism as a therapy for Huntington disease (15 min)
 Sandrine Betuing

5. Summary and practical tips (15 min)

#### 16:00 - 16:15 BREAK

16:15 - 17:45 PLENARY SESSION IV: Upcoming Clinical Trials Chaired by: Jean-Marc Burgunder and Sarah Tabrizi

SOM Biotech (15 min)
 TBD
 Novartis (15 min)
 Beth Borowsky
 Voyager (15 min)
 Maria Lopez-Bresnahan
 PTC (15 min)
 Brian Pfister
 Enroll-HD Platform Studies (10 min)
 Olivia Handley
 HDClarity (5 min)
 Ed Wild
 Panel discussion (15 min)
 all speakers from Plenary Session IV

## 17:45 - 18:00 BREAK

## 18:00 - 18:45 KEYNOTE SESSION II: Outlook Chaired by: Dina de Sousa and Giorgos Papantoniou New staging system in HD extending the window of testing and treatment Cristina Sampaio (30 min) Q&A (15 min)

## 18:45 - 19:15 ROUND-UP and Goodbye for the day Historical perspective (10 min) Tom Bird Goodbye (5 min) Host Patrick Weydt with Astri Arnesen and Matthew Ellison